Charles River Laboratories International CRL
NYSE CRL
$282.06 +8.65 (+3.16%)
As of: Sep 17, 2026 · 3:59 PM EDT

Charles River Laboratories International (CRL) Capital Expenditures Growth (3y) (2012 - 2026)

Analysis

Charles River Laboratories International (CRL) Capital Expenditures Growth (3y) (2012 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capex Growth (3y) (Qtr)
1 Iqvia Holdings 44.72 Bn 42.64 Bn 1.44 Bn 7.36%
2 Medpace Holdings 17.37 Bn 16.87 Bn 201.64 Mn 41.46%
3 Icon 13.65 Bn 12.72 Bn 479.29 Mn -9.70%
4 Charles River Laboratories International 13.13 Bn 12.94 Bn 452.07 Mn -22.72%
5 Fortrea Holdings 1.89 Bn 1.72 Bn 139.20 Mn -2.13%
6 Evotec SE 574.75 Mn 148.87 Mn - -
7 Ginkgo Bioworks Holdings 439.63 Mn 355.09 Mn 18.44 Mn -42.16%
8 Champions Oncology 69.43 Mn 65.03 Mn 7.70 Mn -42.80%
9 MindWalk Holdings 51.76 Mn 46.29 Mn 1.61 Mn 18.12%
10 VivoSim Labs 1.37 Mn 1.37 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 27, 2026 -22.72%
Mar 28, 2026 -19.43%
Dec 27, 2025 -0.03%
Sep 27, 2025 -21.08%
Jun 28, 2025 -24.75%
Mar 29, 2025 -9.66%
Dec 28, 2024 -8.52%
Sep 28, 2024 -11.33%
Jun 29, 2024 -5.26%
Mar 30, 2024 41.34%
Dec 30, 2023 -3.76%
Sep 30, 2023 36.05%
Jul 1, 2023 35.98%
Apr 1, 2023 60.77%
Dec 31, 2022 11.72%
Sep 24, 2022 27.21%
Jun 25, 2022 49.53%
Mar 26, 2022 68.80%
Dec 25, 2021 12.88%
Sep 25, 2021 35.27%